Vanguard Group Inc. Trims Holdings in Hologic, Inc. $HOLX

Vanguard Group Inc. lessened its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 2.2% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 26,213,728 shares of the medical equipment provider’s stock after selling 587,955 shares during the quarter. Vanguard Group Inc. owned about 11.79% of Hologic worth $1,769,165,000 as of its most recent filing with the SEC.

Other large investors have also recently added to or reduced their stakes in the company. Invesco Ltd. increased its position in Hologic by 72.5% during the second quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock worth $543,486,000 after buying an additional 3,505,828 shares during the period. Illinois Municipal Retirement Fund increased its stake in Hologic by 20.4% in the third quarter. Illinois Municipal Retirement Fund now owns 172,294 shares of the medical equipment provider’s stock valued at $11,628,000 after purchasing an additional 29,143 shares during the period. K.J. Harrison & Partners Inc purchased a new stake in shares of Hologic in the second quarter valued at about $1,987,000. New York State Common Retirement Fund grew its holdings in shares of Hologic by 16.3% during the third quarter. New York State Common Retirement Fund now owns 142,622 shares of the medical equipment provider’s stock worth $9,626,000 after buying an additional 20,000 shares during the last quarter. Finally, ING Groep NV acquired a new position in Hologic in the 3rd quarter valued at about $1,941,000. 94.73% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. BNP Paribas Exane lowered Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 target price on the stock. in a report on Friday, November 21st. Mizuho downgraded shares of Hologic from an “outperform” rating to a “neutral” rating and boosted their price objective for the stock from $70.00 to $78.00 in a research note on Thursday, October 23rd. Argus lowered Hologic from a “buy” rating to a “hold” rating in a research report on Monday, January 12th. Morgan Stanley raised their target price on Hologic from $69.00 to $76.00 and gave the company an “equal weight” rating in a report on Tuesday, November 11th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hologic in a report on Wednesday, January 28th. Two analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company’s stock. Based on data from MarketBeat, Hologic has a consensus rating of “Hold” and a consensus price target of $78.42.

Hologic Trading Down 0.0%

Shares of HOLX opened at $75.17 on Friday. The business’s 50-day moving average price is $74.91 and its 200 day moving average price is $71.80. The company has a current ratio of 4.04, a quick ratio of 3.32 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $16.78 billion, a P/E ratio of 31.31, a P/E/G ratio of 2.24 and a beta of 0.72. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $75.36.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). Hologic had a net margin of 13.18% and a return on equity of 19.58%. The firm had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the prior year, the firm earned $0.87 EPS. The firm’s revenue was up 2.5% compared to the same quarter last year. Analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.